Sort by
Refine Your Search
-
Category
-
Country
-
Employer
-
Field
-
Position Qualification Position Summary Postdoctoral Research Associate – Computational Medical Physics / Adaptive Radiotherapy The Department of Radiation Oncology at the University of Nebraska Medical
-
Appointment Term: 1-year term with possible extension Appointment Start Date: As soon as possible Group or Departmental Website: https://med.stanford.edu/gulab (link is external) http://med.stanford.edu
-
Physics / Adaptive Radiotherapy The Department of Radiation Oncology at the University of Nebraska Medical Center (UNMC) is seeking applications for a Postdoctoral Research Associate position. The research
-
°C, is applied in combination with radiotherapy and/or chemotherapy to improve clinical outcome. In recent years, the ability of hyperthermia to dramatically enhance tumour control rates and even
-
goal. About the research project Hyperthermia therapy, i.e heating of tumour tissue in the range of 40–44°C, is applied in combination with radiotherapy and/or chemotherapy to improve clinical outcome
-
supercomputer (https://dcai.dk/gefion ). Downstream finetuning of models for various radiotherapy related tasks (e.g. image segmentation, dose prediction) will also be a part of the study. As part of the position
-
countries that have RT. The project aims to design and prototype a radiotherapy treatment system tailored to challenging environments http://cerncourier.com/a/how-to-democratise-radiation-therapy
-
Research Scholarship of Post-Doctoral Research for the scientific area of Chemistry - IST/2025/BL103
Conjugates for Targeted Chemotherapy and Radiotherapy Duration: 12 months Maximum Duration Including Renewals: 24 months Objectives Design and synthesize optimized FAP binding proteins possessing varying
-
therapy combined with standard treatment can extend patient survival by 10–12 months. We have also demonstrated that radiotherapy induces reactivation of HCMV in approximately 50% of patients, placing
-
patient outcome. Importantly, our clinical studies show that antiviral therapy, when combined with standard treatment, can extend patient survival by 10–12 months. We have further shown that radiotherapy